Atara Biotherapeutics
ATRA
84 hedge funds and large institutions have $360M invested in Atara Biotherapeutics in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 12 closing their positions.
72% more call options, than puts
Call options by funds: $1.44M | Put options by funds: $836K
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
0.24% more ownership
Funds ownership: 3.3% → 3.54% (+0.24%)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 12
27% less capital invested
Capital invested by funds: $493M → $360M (-$132M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.5M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$6.33M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$5.39M |
| 4 |
RI
RTW Investments
New York
|
+$4.07M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.94M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.68M |
| 3 |
State Street
Boston,
Massachusetts
|
-$2.94M |
| 4 |
Goldman Sachs
New York
|
-$2.88M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.48M |
ATRA Hedge Fund Activity: Q2 2017 in Review
84 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q2 2017, worth a combined $360M — down 27% from $493M a quarter earlier.
Fund positioning in ATRA was balanced in Q2 2017: 12 funds opened new positions, 12 closed out, 31 added to existing stakes and 22 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12.5M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.94M sold.
- 84 institutional investors held Atara Biotherapeutics (ATRA) as of Q2 2017, unchanged from Q1 2017.
- Funds reported $360M of Atara Biotherapeutics stock for Q2 2017, down 27% quarter-over-quarter.
- 12 funds opened new Atara Biotherapeutics positions in Q2 2017 and 12 closed out, a net change of 0 holders.
- The largest Atara Biotherapeutics buyer in Q2 2017 was Morgan Stanley, an estimated $12.5M added.
- The largest Atara Biotherapeutics seller in Q2 2017 was EcoR1 Capital, an estimated $8.94M sold.
Based on aggregated 13F filings for Q2 2017.